BIOMAT Database Logo BIOMAT Database Logo

Chronic antihypertensive effects of captopril (SQ 14,225), an orally active angiotensin I-converting enzyme inhibitor, in conscious 2-kidney renal hypertensive rats. 1978

B Rubin, and M J Antonaccio, and M E Goldberg, and D N Harris, and A G Itkin, and Z P Horovitz, and R E Panasevich, and R J Laffan

Indirect systolic blood pressure (SBP) was monitored in 9 groups of 15 male conscious 2-kidney renal hypertensive rats (RHR) for over 6 months. Daily oral dosing with captopril (SQ 14,225, D-3-mercapto-2-methylpropanoyl-L-proline, 30 mg/kg), an orally active angiotensin I-converting enzyme inhibitor, lowered SBP 30--50 MM Hg during this period. Withdrawal of captopril for 5 days at 1, 3 and 6 months resulted in gradual return of SBP to control levels without overshoot. Resumption of dosage with captopril again decreased SBP. Daily oral dosing with hydrochlorothiazide (HCTZ, 6 mg/kg/day) alone for 6 months had little or no effect on SBP, but increased the antihypertensive effect of captopril. Daily oral dosing with hydralazine (6 mg/kg) caused an initial marked antihypertensive effect greater than that of captopril but almost complete tolerance developed within 4 weeks of dosing. Highest survival rates occurred in RHR treated with captopril plus HCTZ. In four other similarly treated groups of RHR and normotensive rats (NR), least cardiac hypertrophy and highest plasma renin activity occurred in captopril-treated animals compared with vehicle-treated controls. Plasma renin activity was about 2 to 4 fold higher in the rats dosed with captopril compared with vehicle-treated rats. Heart weight/body weight ratios, initially higher in the two RHR groups compared to NR, decreased only in the captopril treated group to or near those of the NR groups. These results indicate that chronic treatment with captopril decreased SBP and cardiac weights of RHR, and that HCTZ, or possibly other diuretics, can augment the antihypertensive effect of captopril while having little or no effect by themselves.

UI MeSH Term Description Entries
D006977 Hypertension, Renal Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN. Hypertensions, Renal,Renal Hypertension,Renal Hypertensions
D008297 Male Males
D009929 Organ Size The measurement of an organ in volume, mass, or heaviness. Organ Volume,Organ Weight,Size, Organ,Weight, Organ
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

B Rubin, and M J Antonaccio, and M E Goldberg, and D N Harris, and A G Itkin, and Z P Horovitz, and R E Panasevich, and R J Laffan
Antihypertensive activity of captopril (SQ 14,225), an orally active inhibitor of angiotensin converting enzyme in conscious two-kidney perinephritic hypertensive dogs.
February 1981, The Journal of pharmacology and experimental therapeutics,
B Rubin, and M J Antonaccio, and M E Goldberg, and D N Harris, and A G Itkin, and Z P Horovitz, and R E Panasevich, and R J Laffan
Antihypertensive activity in rats for SQ 14,225, an orally active inhibitor of angiotensin I-converting enzyme.
February 1978, The Journal of pharmacology and experimental therapeutics,
B Rubin, and M J Antonaccio, and M E Goldberg, and D N Harris, and A G Itkin, and Z P Horovitz, and R E Panasevich, and R J Laffan
Hemodynamic and antihypertensive effects of captopril, an orally active angiotensin converting enzyme inhibitor.
January 1979, Hypertension (Dallas, Tex. : 1979),
B Rubin, and M J Antonaccio, and M E Goldberg, and D N Harris, and A G Itkin, and Z P Horovitz, and R E Panasevich, and R J Laffan
Usefulness of orally active angiotensin I converting enzyme inhibitor (SQ 14,225) in the treatment of malignant hypertension.
March 1980, Fukuoka igaku zasshi = Hukuoka acta medica,
B Rubin, and M J Antonaccio, and M E Goldberg, and D N Harris, and A G Itkin, and Z P Horovitz, and R E Panasevich, and R J Laffan
SQ 14,225 (D-3-mercapto-2-methylpropanoyl-l-proline), a novel orally active inhibitor of angiotensin I-converting enzyme.
February 1978, The Journal of pharmacology and experimental therapeutics,
B Rubin, and M J Antonaccio, and M E Goldberg, and D N Harris, and A G Itkin, and Z P Horovitz, and R E Panasevich, and R J Laffan
Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.
January 1985, Arzneimittel-Forschung,
B Rubin, and M J Antonaccio, and M E Goldberg, and D N Harris, and A G Itkin, and Z P Horovitz, and R E Panasevich, and R J Laffan
Potentiation of the algogenic action of bradykinin by an inhibitor of angiotensin I converting enzyme, captopril (SQ 14,225).
August 1979, Japanese journal of pharmacology,
B Rubin, and M J Antonaccio, and M E Goldberg, and D N Harris, and A G Itkin, and Z P Horovitz, and R E Panasevich, and R J Laffan
Inhibition of angiotensin converting enzyme by SQ 14,225 in conscious rabbits.
December 1977, European journal of pharmacology,
B Rubin, and M J Antonaccio, and M E Goldberg, and D N Harris, and A G Itkin, and Z P Horovitz, and R E Panasevich, and R J Laffan
Hypotensive action of angiotensin I converting enzyme inhibitor (SQ 14,225) in nephrectomized dogs.
July 1982, The Journal of pharmacology and experimental therapeutics,
B Rubin, and M J Antonaccio, and M E Goldberg, and D N Harris, and A G Itkin, and Z P Horovitz, and R E Panasevich, and R J Laffan
The effect of acute administration of an angiotensin converting enzyme inhibitor, captopril (SQ 14,225), on experimentally induced thirsts in rats.
January 1980, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!